{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:47:29Z","timestamp":1770461249064,"version":"3.49.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes <jats:italic>in vivo<\/jats:italic>, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the advantages of siRNA technology while also overcoming its limitations, we designed a new strategy and prepared biomimetic nanoparticles that were directed by PreS\/2-21 peptides and precisely loaded HBV siRNA. Experiments on these nanoparticles <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> revealed that they are tiny, stable, safe and highly targetable, with high inhibitory effects on HBV DNA, pgRNA, cccDNA, HBeAg and HBsAg. PreS\/2-21-directed nanoparticles loaded with HBV gene therapy drugs are expected to be promising for the treatment of CHB.<\/jats:p>","DOI":"10.3389\/fimmu.2022.856463","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:32:43Z","timestamp":1651210363000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["PreS\/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication"],"prefix":"10.3389","volume":"13","author":[{"given":"Lixia","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhentian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiancai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global Prevalence, Treatment, and Prevention of Hepatitis B Virus Infection in 2016: A Modelling Study","volume":"3","author":"Collaborators","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/v12030285","article-title":"The Interactions Between HBV and the Innate Immunity of Hepatocytes","volume":"12","author":"Megahed","year":"2020","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A Global Scientific Strategy to Cure Hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03127","article-title":"Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection","volume":"10","author":"Meng","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa286","article-title":"Generation and Validation of Structurally Defined antibody-siRNA Conjugates","volume":"48","author":"Nanna","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1976","DOI":"10.1002\/rmv.1976","article-title":"A Review on Current Status of Antiviral siRNA","volume":"28","author":"Qureshi","year":"2018","journal-title":"Rev Med Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12985-021-01509-z","article-title":"Immunostimulatory siRNA With a Uridine Bulge Leads to Potent Inhibition of HBV and Activation of Innate Immunity","volume":"18","author":"Lan","year":"2021","journal-title":"Virol J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i44.12558","article-title":"Hepatitis B Virus Therapy: What's the Future Holding for Us","volume":"21","author":"Manzoor","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13304","article-title":"Future Anti-HBV Strategies","author":"Gane","year":"2017","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b21214","article-title":"Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA\/miRNA Combination Cancer Therapy","volume":"12","author":"Wang","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1248\/yakushi.123.25","article-title":"Chemotherapy With Hybrid Liposomes Without Any Drug In Vivo","volume":"123","author":"Ichihara","year":"2003","journal-title":"Yakugaku Zasshi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium Taurocholate Cotransporting Polypeptide is a Functional Receptor for Human Hepatitis B and D Virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.3.193","article-title":"From DCPD to NTCP: The Long Journey Towards Identifying a Functional Hepatitis B Virus Receptor","volume":"21","author":"Li","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.13431\/j.cnki.immunol.j.20140052","article-title":"The Research of Nano-Liposome Targeting Hepatocyte Mediated by Pre S1 Peptide (2-21Aa)","volume":"30","author":"Han","year":"2014","journal-title":"Immunol J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-9455.2020.21.009","article-title":"Antiviral Effect Of Antigene Olocked Nucleic Acid of HBV Pres1, Pres2 Coding Chain on HepG 2.2.15 Cells","volume":"17","author":"Peng","year":"2020","journal-title":"Lab Med Clin"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05344-11","article-title":"Hepatocytes Traffic and Export Hepatitis B Virus Basolaterally by Polarity-Dependent Mechanisms","volume":"85","author":"Bhat","year":"2011","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0016-5085(03)00720-0","article-title":"Inhibition of Hepatitis B Virus Replication In Vivo by Nucleoside Analogues and siRNA","volume":"125","author":"Klein","year":"2003","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/hep.21663","article-title":"Targeted Inhibition of HBV Gene Expression by Single-Chain Antibody Mediated Small Interfering RNA Delivery","volume":"46","author":"Wen","year":"2007","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24505","article-title":"Reversal of Hepatitis B Virus-Induced Immune Tolerance by an Immunostimulatory 3p-HBx-siRNAs in a Retinoic Acid Inducible Gene I-Dependent Manner","volume":"54","author":"Han","year":"2011","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1333105","article-title":"New Antivirals for the Treatment of Chronic Hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30248","article-title":"Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR-192-3p-XIAP Through NF Kappa B Signaling","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatol (Baltimore Md)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2017.16","article-title":"A non-Viral CRISPR\/Cas9 Delivery System for Therapeutically Targeting HBV DNA and Pcsk9 In Vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect Against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15197","article-title":"The Antiviral Effects of Human microRNA miR-302c-3p Against Hepatitis B Virus Infection","volume":"49","author":"Hamada-Tsutsumi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2005.12.012","article-title":"Efficient Inhibition of Hepatitis B Virus Replication by Small Interfering RNAs Targeted to the Viral X Gene in Mice","volume":"119","author":"Shin","year":"2006","journal-title":"Virus Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic Hepatitis B: Virology, Natural History, Current Management and a Glimpse at Future Opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.01.007","article-title":"Role of HBx in Hepatitis B Virus Persistence and its Therapeutic Implications","volume":"30","author":"Slagle","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00248-19","article-title":"Spatiotemporal Analysis of Hepatitis B Virus X Protein in Primary Human Hepatocytes","volume":"93","author":"Kornyeyev","year":"2019","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-008-0308-1","article-title":"Targeted Screening of SiRNA Directed HBV Polymerase Gene for Effective Inhibition of HBV Expression","volume":"28","author":"Yao","year":"2008","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2012.11.013","article-title":"PreC\/C Gene-Targeting RNA Interference Suppresses Hepatitis B Virus Replication and Expression in Human Hepatoma Cells","volume":"92","author":"Bian","year":"2012","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/hepr.12189","article-title":"Targeted Delivery of siRNA Against Hepatitis B Virus by Pres1 Peptide Molecular Ligand","volume":"44","author":"Huang","year":"2014","journal-title":"Hepatol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.antiviral.2018.11.006","article-title":"5\u2032-Triphosphate siRNA Targeting HBx Elicits a Potent Anti-HBV Immune Response in pAAV-HBV Transfected Mice","volume":"161","author":"Han","year":"2019","journal-title":"Antiviral Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA Therapeutics: A Clinical Reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci China Life Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00582","article-title":"New Chemical Modalities and Strategic Thinking in Early Drug Discovery","volume":"11","author":"Blanco","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/ph12020052","article-title":"2018 FDA Tides Harvest","volume":"12","author":"Al Shaer","year":"2019","journal-title":"Pharmaceut (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1128\/JVI.01902-09","article-title":"Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction","volume":"84","author":"Schulze","year":"2010","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12117","article-title":"In Silico Analysis and Experimental Validation of Azelastine Hydrochloride (N4) Targeting Sodium Taurocholate Co-Transporting Polypeptide (NTCP) in HBV Therapy","volume":"47","author":"Fu","year":"2014","journal-title":"Cell Prolif"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.01.003","article-title":"Hepatitis B: Current Status of Therapy and Future Therapies","volume":"49","author":"Spyrou","year":"2020","journal-title":"Gastroenterol Clinics North America"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/microorganisms8091416","article-title":"Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection","volume":"8","author":"Rybicka","year":"2020","journal-title":"Microorganisms"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03540-12","article-title":"Molecular Determinants of Hepatitis B and D Virus Entry Restriction in Mouse Sodium Taurocholate Cotransporting Polypeptide","volume":"87","author":"Yan","year":"2013","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15022892","article-title":"NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry","volume":"15","author":"Watashi","year":"2014","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.856463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:33:02Z","timestamp":1651210382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.856463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2022.856463"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.856463","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"article-number":"856463"}}